Previous 10 | Next 10 |
Vaccinex (NASDAQ: VCNX ): Q1 Revenue of $0.09M (-55.0% Y/Y) Cash and cash equivalents and marketable securities of $11.3M. Press Release More news on: Vaccinex, Inc., Earnings news and commentary, Healthcare stocks news, ,
ROCHESTER, N.Y., May 15, 2019 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and Huntington’s disease, today announced that two posters on its lead monoclonal antibody candidate, ...
Updated interim data from CLASSICAL-Lung study to be presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in June 2019 Enrollment in Phase 2 SIGNAL Huntington’s disease trial complete; data expected in 2H 2020 ROCHESTER, N.Y., May 15, 2019 (GLO...
Gainers : Fibrocell Science (NASDAQ: FCSC ) +52% . Bio-Path Holdings (NASDAQ: BPTH ) +40% . Vectrus (NYSE: VEC ) +27% . Electronics for Imaging (NASDAQ: EFII ) +27% . SSLJ.com (NASDAQ: SSLJ ) +22% . ATA (NASDAQ: ATAI ) +21% . Advanced Disposal Services (NYSE: ADSW ) +19% . Amy...
ROCHESTER, N.Y., April 09, 2019 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and Huntington’s disease today summarizes key data on the company’s anti-SEMA4D tec...
Gainers: AVEO Pharmaceuticals (NASDAQ: AVEO ) +35% . ADMA Biologics (NASDAQ: ADMA ) +32% . Sangamo Therapeutics (NASDAQ: SGMO ) +27% . Castor Maritime (NASDAQ: CTRM ) +24% . EDAP TMS S.A. (NASDAQ: EDAP ) +23% . Riot Blockchain (NASDAQ: RIOT ) +22% . Vaccinex (NASDAQ: VCNX ) +1...
ROCHESTER, N.Y., April 01, 2019 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and Huntington’s disease today announces it will be posting on its website each of the thr...
ROCHESTER, N.Y., March 13, 2019 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and Huntington’s disease, today announced that it will be presenting at Oppenheimer & Co.’...
Vaccinex (NASDAQ: VCNX ): FY net loss of $29.5M More news on: Vaccinex, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Initial data from ongoing open label study of pepinemab (VX15/2503) in combination with avelumab in non-small cell lung cancer expected in 2Q 2019 Enrollment in cohort B of the Phase 2 SIGNAL Huntington’s disease trial complete; data expected in 2H 2020 ROCHESTER, N.Y., Marc...
News, Short Squeeze, Breakout and More Instantly...
Company expects to lock database in June and remains on track to report key outcomes later in July. Pepinemab targets astrocyte reactivity and neuroinflammation, believed to be key drivers of neurodegeneration. ROCHESTER, N.Y., June 06, 2024 (GLOBE NEWSWIRE) -- Vaccinex, I...
A look at the top 10 most actives in the United States Novo Integrated Sciences Inc. (NVOS) rose 132.8% to $1.05 on volume of 308,155,573 shares Greenwave Technology Solutions Inc. (GWAV) fell 7.9% to $0.0387 on volume of 278,348,616 shares Faraday Future Intelligent Electric Inc. (FFIE) ...
Vaccinex, Inc. (NASDAQ: VCNX) is one of today's top gainers. The company's shares have moved 15.16% on the day to $6. Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet...